RM Law is investigating potential claims against the board of directors of Albany Molecular Research, Inc. (“Albany Molecular” or the “Company”) (NASDAQ: AMRI).
If you own shares of Albany Molecular and would like to learn more about this class action or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/amri. You may also email Mr. Maniskas at firstname.lastname@example.org.
Albany Molecular is a contract research and manufacturing company that provides integrated drug discovery, development and manufacturing services primarily in the United States, Europe and Asia. The complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose material adverse facts about the Company’s operations, financial performance and prospects, including the Company’s financial guidance and operations at its OsoBio facility.
On November 5, 2014, the Company announced weak financial and operating results for third quarter 2014, including an $8.6 million loss in the quarter. The Company attributed the weak third quarter to a “confluence of a business interruption event at our OsoBio facility, together with lower Discovery and API revenue.” In addition, the Company disclosed a “weather-related power interruption at our OsoBio facility in Albuquerque took the facility offline for a period of time, contributing to the loss of finished product and the need to remediate one of the suites at the facility.” Following this news, Albany Molecular stock declined nearly 27%, or $6.08 per share, to close at $16.59 per share on November 5, 2014.